Pharmacodynamic biomarker quantitates pharmaceutical target engagement predicting therapeutic efficacy. Receptor occupancy assessment determines target saturation. Pathway activation quantitation indicates mechanism engagement. Biomarker response precedes clinical benefit enabling early assessment. Dose-biomarker relationships characterise target engagement kinetics.
Regulatory submissions employ biomarker evidence supporting efficacy. Clinical outcomes correlate with biomarker changes. Biomarker-driven dosing optimises therapy. Post-approval monitoring confirms biomarker predictions. Emerging imaging enables visualised biomarker assessment.
Pharmacokinetics & Pharmacodynamics (PK/PD)
Pharmacodynamic Biomarker
A pharmacodynamic biomarker is a measurable biological indicator that demonstrates a therapeutic product's biological activity or pharmacological effect.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →